Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study

Main Article Content

Kim A Papp
Joseph F Merola
Alice B Gottlieb
Christopher EM Griffiths
Kristina K Harris
Nancy Cross
Luke Peterson
Christopher Cioffi
Andrew Blauvelt

Keywords

psoriasis, bimekizumab

Abstract

Abstract not available.

References

1. Glatt S et al. Br J Clin Pharmacol. 2017;83:991-1001.

2. Papp KA et al. J Am Acad Dermatol. 2018:79:279-286.

3. Papp KA et al. EADV. 2018 [e poster P1978].

4. Blauvelt A et al. AAD. 2019 (oral presentation OP11180).

5. Armstrong AW et al. PLoS One. 2012;7(12):e52935.

6. Strober B et al. BMJ Open. 2019;9(4): e027535.

7. Griffiths CEM et al. Br J Dermatol. 2018;179:173-181.

8. Korman NJ et al. Dermatol Online J. 2015;21(10):pii: 13030/qt1x16v3dg

9. Augustin M et al. Br J Dermatol 2018;179:1385-1391.